“This points more toward a model where the tumor is cleared and the T cells largely go away,” Hinrichs noted in the interview ...

Groundbreaking studies reveal the potential of cell therapies to achieve long-term remission in HPV-associated cancers, ...

This segment offers an up-to-date overview of current treatment standards and diagnostic practices in advanced esophageal ...

Giredestrant significantly improves IDFS in ER-positive, HER2-negative early-stage breast cancer, surpassing standard ...

Bispecific and trispecific antibodies show efficacy in multiple myeloma, moving into earlier lines of therapy.

During a live event, Moshe C. Ornstein, MD, MA, considered the trial design and outcomes of 2 trials of combination regimens ...

Future SCLC treatment may involve combining T-cell engagers with immune checkpoint inhibitors to enhance patient outcomes.

OBI-902, targeting TROP2, gains FDA orphan drug status for cholangiocarcinoma, a rare cancer with poor prognosis and limited treatments. Orphan drug designation provides benefits like tax credits and ...

FDA fast track designation facilitates expedited development of DPTX3186, recognizing its potential to address serious unmet medical needs in gastric cancer treatment. DPTX3186 gains FDA fast track ...

Ongoing research in renal cell carcinoma (RCC) suggests that hypoxia-inducible factor 2-alpha (HIF-2α) inhibitors are poised ...

Benjamin, MD, discussed findings on the global oncology workforce and their implications of insufficient access to cancer ...

In an interview with Targeted Oncology, David J. Benjamin, MD, discussed findings on the global oncology workforce and their ...